Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants with Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT06051695
Recruiting
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express MSLN and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose of A2B694 that is safe for patients Phase 2: Does the recommended do... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Register for Updates
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL
NCT03666000
Recruiting
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Register for Updates
Brain Training for Substance Use Disorders
NCT06870110
Recruiting
Participants play games designed to train visual attention towards natural, non-drug-related scenarios. A biofeedback loop between gameplay and an electroencephalogram (EEG) system monitors game performance and guides game difficulty.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2025
Locations: University of Minnesota - Department of Psychiatry & Behavioral Health, Minneapolis, Minnesota
Conditions: Opioid Use Disorder
Register for Updates
CBIT+TMS R33 Phase
NCT06678737
Recruiting
Chronic tics are a disabling neuropsychiatric symptom associated with multiple child-onset mental disorders. Chronic tics affect 1-3% of youth 1 and are associated with impaired functioning, emotional and behavioral problems, physical pain, diminished quality of life, peer victimization, and a fourfold increased risk of suicide compared to the general population. Large randomized trials have demonstrated the superiority of CBIT over supportive therapy in child and adult patients. However, in the... Read More
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
03/05/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Tics, Tourette Syndrome
Register for Updates
Gut Microbiome Studies in Patients with POEMS Syndrome and Other Plasma Cell Disorders
NCT06252948
Recruiting
A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Plasma Cell Disorders
Register for Updates
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
NCT06212193
Recruiting
Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/05/2025
Locations: Mayo Clinic Hospital (Rochester), Rochester, Minnesota
Conditions: Tricuspid Regurgitation, Tricuspid Regurgitation Functional
Register for Updates
ChronoMet: Metabolic and Inflammatory Effects of Eating Timing and Quantity
NCT06161337
Recruiting
This is an observational study to address the important knowledge gap of the metabolic and inflammatory impact of acute overeating and whether timing of acute overeating may modify these effects. The hypothesis is that acute overconsumption of calories will promote inflammation and metabolic dysfunction, with the most detrimental effects observed with evening caloric overconsumption. The expectation is that this study to provide critical insights into the biological consequences of overeating, w... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Healthy Volunteers
Register for Updates
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
NCT05890729
Recruiting
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/05/2025
Locations: Xentria Investigative Site, Minneapolis, Minnesota
Conditions: Pulmonary Sarcoidosis
Register for Updates
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
NCT04925375
Recruiting
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Fu... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
03/05/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Interstitial Lung Disease, Common Variable Immunodeficiency
Register for Updates
IV Gallium Study for Patients with Cystic Fibrosis Who Have NTM (ABATE Study)
NCT04294043
Recruiting
The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA Office of Orphan Products Development (OOPD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: The Minnesota Cystic Fibrosis Center, Minneapolis, Minnesota
Conditions: Nontuberculous Mycobacterium Infection
Register for Updates
Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients with Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
NCT06639074
Recruiting
This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopian tube or primary peritoneal cancer. FRαDCs, a dendritic cell vaccine, is made from a person's white blood cells. The white blood cells are treated in the laboratory to make dendritic cells (a type of immune cell) mixed with folate receptor alpha (FRalpha), a protein found in high levels on ovarian tumor cells. FRαDCs work by boosting the... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
Register for Updates
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
NCT06536452
Recruiting
This study evaluates hematopoiesis to determine how MBL/CLL affected bone marrow responds to fight off infections in the body.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/04/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis
Register for Updates